Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2017

01-12-2017 | Epidemiology

Increased risk of arterial thromboembolism in older men with breast cancer

Authors: Anne S. Reiner, Babak B. Navi, Lisa M. DeAngelis, Katherine S. Panageas

Published in: Breast Cancer Research and Treatment | Issue 3/2017

Login to get access

Abstract

Purpose

Male breast cancer is a rare and understudied disease predominantly affecting men over age 60. Risk of arterial thromboembolic events (ATE) in men increases with age. We examined ATE risk following primary breast cancer diagnosis in elderly men.

Methods

Men with primary breast cancer diagnoses from 2002 to 2011 were identified using the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. Cases were individually matched by age, sex, race, registry, and comorbidities with controls without cancer using SEER-Medicare’s 5% noncancer sample. Medicare claims were used to identify ATE, defined as myocardial infarction or ischemic stroke. Cumulative incidence of ATE was calculated using competing risk methodology, with death considered a competing event. Cox proportional hazards analysis was used to compare rates of ATE among cases and controls.

Results

Three months following primary breast cancer diagnosis, ATE risk in the cohort of 881 men was 80% higher than matched controls (hazard ratio 1.8; 95% confidence interval 1.0–3.2). Six months post-cancer diagnosis, 5.7% of cases had experienced ATE, whereas only 3.5% of controls had (HR 1.6; 95% CI 1.0–2.6). ATE risk remained elevated 12 months post-cancer diagnosis. Among cases, risk of death was threefold higher in men who developed ATE.

Conclusions

We provide population-based evidence that male breast cancer patients have a substantially elevated risk of ATE in the first year following a cancer diagnosis compared with matched controls. Care providers should consider this heightened risk when evaluating cardiovascular health in men with a recent breast cancer diagnosis.
Literature
2.
go back to reference Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004) Breast carcinoma in men. Cancer 101(1):51–57CrossRefPubMed Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004) Breast carcinoma in men. Cancer 101(1):51–57CrossRefPubMed
3.
go back to reference Anderson WF, Jatoi I, Tse J, Rosenberg PS (2010) Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 28(2):232–239CrossRefPubMed Anderson WF, Jatoi I, Tse J, Rosenberg PS (2010) Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 28(2):232–239CrossRefPubMed
4.
go back to reference Silvestri V, Barrowdale D, Mulligan AM et al (2016) Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 18(1):15CrossRefPubMedPubMedCentral Silvestri V, Barrowdale D, Mulligan AM et al (2016) Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 18(1):15CrossRefPubMedPubMedCentral
5.
go back to reference Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M, Gulino M, Frati P, Ottini L (2013) Male breast cancer: genetics, epigenetics, and ethical aspects. Ann Oncol 24(Suppl 8):viii75–viii82CrossRefPubMed Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M, Gulino M, Frati P, Ottini L (2013) Male breast cancer: genetics, epigenetics, and ethical aspects. Ann Oncol 24(Suppl 8):viii75–viii82CrossRefPubMed
6.
go back to reference Mozaffarian D, Benjamin EJ, Go AS et al (2015) Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131(4):e29–e322CrossRefPubMed Mozaffarian D, Benjamin EJ, Go AS et al (2015) Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131(4):e29–e322CrossRefPubMed
7.
go back to reference Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS (2010) Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 362(23):2155–2165CrossRefPubMed Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS (2010) Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 362(23):2155–2165CrossRefPubMed
8.
go back to reference Navi BB, Reiner AS, Kamel H, Iadecola C, Elkind MSV, Panageas KS, DeAngelis LM (2015) Association between incident cancer and subsequent stroke. Ann Neurol 77(2):291–300CrossRefPubMedPubMedCentral Navi BB, Reiner AS, Kamel H, Iadecola C, Elkind MSV, Panageas KS, DeAngelis LM (2015) Association between incident cancer and subsequent stroke. Ann Neurol 77(2):291–300CrossRefPubMedPubMedCentral
9.
go back to reference Zoller B, Ji J, Sundquist J, Sundquist K (2012) Risk of haemorrhagic and ischaemic stroke in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer 48(12):1875–1883CrossRefPubMed Zoller B, Ji J, Sundquist J, Sundquist K (2012) Risk of haemorrhagic and ischaemic stroke in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer 48(12):1875–1883CrossRefPubMed
10.
go back to reference Zoller B, Ji J, Sundquist J, Sundquist K (2012) Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer 48(1):121–128CrossRefPubMed Zoller B, Ji J, Sundquist J, Sundquist K (2012) Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer 48(1):121–128CrossRefPubMed
11.
go back to reference Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):IV-3–18 Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):IV-3–18
12.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed
13.
go back to reference Tirschwell DL, Longstreth WT Jr (2002) Validating administrative data in stroke research. Stroke 33(10):2465–2470CrossRefPubMed Tirschwell DL, Longstreth WT Jr (2002) Validating administrative data in stroke research. Stroke 33(10):2465–2470CrossRefPubMed
14.
go back to reference Lakshminarayan K, Larson JC, Virnig B et al (2014) Comparison of Medicare claims versus physician adjudication for identifying stroke outcomes in the Women’s Health Initiative. Stroke 45:815–821CrossRefPubMedPubMedCentral Lakshminarayan K, Larson JC, Virnig B et al (2014) Comparison of Medicare claims versus physician adjudication for identifying stroke outcomes in the Women’s Health Initiative. Stroke 45:815–821CrossRefPubMedPubMedCentral
15.
go back to reference Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH (2004) Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 148:99–104CrossRefPubMed Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH (2004) Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 148:99–104CrossRefPubMed
16.
go back to reference Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DB (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67(2):93–99CrossRefPubMed Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DB (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67(2):93–99CrossRefPubMed
18.
go back to reference Dearborn J, Urrutia VC, Zeiler SR (2014) Stroke and cancer-a complicated relationship. J Neurol Transl Neurosci 2(1):1039PubMedPubMedCentral Dearborn J, Urrutia VC, Zeiler SR (2014) Stroke and cancer-a complicated relationship. J Neurol Transl Neurosci 2(1):1039PubMedPubMedCentral
19.
20.
go back to reference Schwarzbach CJ, Schaefer A, Ebert A, Held V, Bolognese M, Kablau M, Hennerici MG, Fatar M (2012) Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology. Stroke 43(11):3029–3034CrossRefPubMed Schwarzbach CJ, Schaefer A, Ebert A, Held V, Bolognese M, Kablau M, Hennerici MG, Fatar M (2012) Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology. Stroke 43(11):3029–3034CrossRefPubMed
22.
go back to reference Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102(1):14–25CrossRefPubMedPubMedCentral Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102(1):14–25CrossRefPubMedPubMedCentral
23.
go back to reference Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60(24):2504–2512CrossRefPubMed Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60(24):2504–2512CrossRefPubMed
24.
go back to reference Du XL, Xia R, Burau K, Liu C (2011) Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. Med Oncol 28(Suppl 1):S80–S90CrossRefPubMed Du XL, Xia R, Burau K, Liu C (2011) Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. Med Oncol 28(Suppl 1):S80–S90CrossRefPubMed
25.
go back to reference Chavez-MacGregor M, Zhang N, Buchholz T, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31(33):4222–4228CrossRefPubMedPubMedCentral Chavez-MacGregor M, Zhang N, Buchholz T, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31(33):4222–4228CrossRefPubMedPubMedCentral
26.
go back to reference Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL (2005) Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 23(34):8597–8605CrossRefPubMed Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL (2005) Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 23(34):8597–8605CrossRefPubMed
28.
go back to reference Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD (2016) Cardiovascular disease mortality among breast cancer survivors. Epidemiology 27(1):6–13CrossRefPubMedPubMedCentral Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD (2016) Cardiovascular disease mortality among breast cancer survivors. Epidemiology 27(1):6–13CrossRefPubMedPubMedCentral
Metadata
Title
Increased risk of arterial thromboembolism in older men with breast cancer
Authors
Anne S. Reiner
Babak B. Navi
Lisa M. DeAngelis
Katherine S. Panageas
Publication date
01-12-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4433-z

Other articles of this Issue 3/2017

Breast Cancer Research and Treatment 3/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine